Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA2 | Q9HCG7 | 17/20 | 1.00 |
| ▸ | GBA1 | P04062 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | UGCG | Q16739 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17189564 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL3017802 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL17243607 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL3324203 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL13175020 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL6821239 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL13253278 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL3020875 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL2789051 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG | |
| SCHEMBL9797495 | 1.00 | GBA2 (1.00) | GBA2GBA1GAAUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025094117-A1 | SUBSTITUTED INDOLYL COMPOUNDS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEREOF | GT GAIN THERAPEUTICS SA (CH) | 2025-05-08 | — | — | WO | claimed |
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-04-06 | — | — | US | claimed |
| US-20230103407-A1 | MATERIALS AND METHODS FOR THE TREATMENT OF GAUCHER DISEASE | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-04-06 | — | — | US | claimed |
| WO-2023042177-A1 | ENANTIOMERS OF 5-((7-CHLOROISOQUINOLIN-1-YL)AMINO)-N-(6-METHOXY-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)PICOLINAMIDE | GT GAIN THERAPEUTICS SA (CH) | 2023-03-23 | — | — | WO | claimed |
| EP-4117628-A1 | MATERIALS AND METHODS FOR THE TREATMENT OF GAUCHER DISEASE | University of Cincinnati (US) | 2023-01-18 | — | — | EP | claimed |
| CN-115348959-A | Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity | 增益治疗股份有限公司 | 2022-11-15 | — | — | CN | claimed |
| EP-4065563-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | claimed |
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | claimed |
| CN-110494432-B | Isoquinoline compounds, methods of preparation thereof and therapeutic use thereof in disorders associated with altered beta-galactosidase activity | 米尼奥尔克斯治疗有限公司 | 2022-08-12 | — | — | CN | claimed |
| EP-3562811-B1 | HETEROARYL COMPOUNDS AND THEIR USE | MINORYX THERAPEUTICS S L (ES) | 2022-03-16 | — | — | EP | claimed |
| WO-2003037265-A9 | METHOD OF TREATING VIRAL INFECTIONS | UNIV JEFFERSON (US) | 2004-02-19 | — | — | WO | claimed |
| US-6660749-B2 | Administering a dideoxy-imino-glucitol | CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2003-12-09 | — | — | US | claimed |
| US-20030130317-A1 | Inhibition of glycolipid biosynthesis | UNITHER VIROLOGY, LLC | 2003-07-10 | — | — | US | claimed |
| WO-2003037265-A2 | METHOD OF TREATING VIRAL INFECTIONS | THOMAS JEFFERSON UNIVERSITY (US) | 2003-05-08 | — | — | WO | claimed |
| US-6465488-B1 | TREATMENT OF LIPID STORAGE DISEASES USING N-NONYL-1,5-DIDE-OXY-1,5-IMINO-D-GLUCITOL; GLUCOSYLTRANSFERASE INHIBITORS; TAY-SACHS, GAUCHER, KRABBE, OR FABRY DISEASE | CHANCELLOR, MASTERS & SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2002-10-15 | — | — | US | claimed |
| JP-2001525367-A | — | — | 2001-12-11 | — | — | JP | claimed |
| EP-1037636-A1 | INHIBITION OF MEMBRANE-ASSOCIATED VIRAL REPLICATION | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2000-09-27 | — | — | EP | claimed |
| WO-1999029321-A9 | INHIBITION OF MEMBRANE-ASSOCIATED VIRAL REPLICATION | UNIV OXFORD (GB) | 1999-09-16 | — | — | WO | claimed |
| WO-1999029321-A1 | INHIBITION OF MEMBRANE-ASSOCIATED VIRAL REPLICATION | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 1999-06-17 | — | — | WO | claimed |
| US-5030638-A | Applying 1,5-(alkylimino)-1,5-dideoxy-d-glucitol; aids | G. D. SEARLE & CO. (US) | 1991-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GBA1, GBA2, GBA3 | GBA2 2/4885GBA1 1/4885GAA 4/4885 |
| US-20030130317-A1 | Inhibition of glycolipid biosynthesis | UGCG, GBA1, UGGT1 | GBA2 4/4885GBA1 2/4885GAA 9/4885 |
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | GLB1, GBA1, GALC | GBA2 7/4885GBA1 2/4885GAA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.